Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
CAMBRIDGE, Mass., Feb. 01, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, February 15th at 10:30 a.m. ET.
The webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
